Eiger BioPharmaceuticals to Present at the H.C. Wainwright Third Annual Hepatitis B Virus (HBV) Virtual Conference
Eiger BioPharmaceuticals, based in Palo Alto, California, announced that President and CEO David Cory will present a company overview at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Eiger BioPharmaceuticals, based in Palo Alto, California, announced that President and CEO David Cory will present a company overview at the H.C. Wainwright Third Annual Hepatitis B Virus Virtual Conference on October 18, 2022, at 3:00 PM ET. Investors can participate in one-on-one meetings at the conference. A live webcast of the presentation will be available on the company's website, with a replay accessible for at least 90 days. Eiger focuses on innovative therapies for hepatitis delta virus and has several programs designated as FDA Breakthrough Therapy.
Details
News Market Reaction – EIGR
The recorded move for EIGR in the trading session of this news was +4.86%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PALO ALTO, Calif., Oct. 11, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that David Cory, President and CEO, will present a company overview at the H.C. Wainwright Third Annual Hepatitis B Virus (HBV) Virtual Conference on Tuesday, October 18, 2022 at 3:00 PM ET. The company will also host one-on-one meetings with investors at the conference.
A live webcast of the presentation will be available on the Investors section of the Eiger BioPharmaceuticals website at www.eigerbio.com, and a replay will be available on the website for at least 90 days.
Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases. The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. All five Eiger rare disease programs have been granted FDA Breakthrough Therapy designation: lonafarnib/ritonavir for HDV, peginterferon lambda for HDV, avexitide for congenital hyperinsulinism, avexitide for post-bariatric hypoglycemia, and Zokinvy® (lonafarnib) for progeria.
For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
Contacts
Investors:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Media:
Sarah Mathieson
SVP, Corporate Affairs
smathieson@eigerbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-present-at-the-hc-wainwright-third-annual-hepatitis-b-virus-hbv-virtual-conference-301645595.html
SOURCE Eiger BioPharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.